Simplify Logo

Full-Time

Senior Computational Chemistry Research Scientist

Enhanced Sampling

Posted on 6/27/2024

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

Hardware
AI & Machine Learning
Biotechnology
Healthcare

Senior, Expert

Burlingame, CA, USA

Category
Computational Biology
Lab & Research
Biology & Biotech
Required Skills
Python
Requirements
  • PhD in a related field
  • Proven track record in applying sampling methods to complex targets
  • Strong theoretical understanding of sampling methodologies
  • Proficiency in Python programming
Responsibilities
  • Develop and refine sampling methods and protocols
  • Apply advanced sampling techniques such as metadynamics and replica exchange
  • Utilize cluster of GPUs and CPUs for experimentation
  • Collaborate with ML researchers and chemists to deploy improvements

Genesis Therapeutics focuses on accelerating the development of new medicines using artificial intelligence in the drug discovery sector. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables the exploration of new chemical spaces and the discovery of novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide its AI-driven drug discovery services. The company generates revenue through upfront payments and potential future earnings based on the success of the drugs developed through its platform. Genesis Therapeutics aims to transform the drug discovery process and bring critical new medicines to market.

Company Stage

Series B

Total Funding

$256.1M

Headquarters

Burlingame, California

Founded

2019

Growth & Insights
Headcount

6 month growth

23%

1 year growth

32%

2 year growth

128%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recognition as a 'Fierce 15' company and one of America's most promising AI companies highlights Genesis Therapeutics' industry leadership and innovation.
  • The $200M Series B funding will enable the company to advance its AI-enabled pipeline into clinical development, potentially leading to groundbreaking new treatments.
  • Partnerships with industry giants like NVIDIA and Eli Lilly provide substantial opportunities for growth and collaboration.

What critics are saying

  • The highly competitive biotech and AI-driven drug discovery sectors may pose challenges in maintaining a unique market position.
  • Dependence on strategic partnerships and funding rounds could impact financial stability if future deals or investments do not materialize.

What makes Genesis Therapeutics unique

  • Genesis Therapeutics leverages a unique combination of 3D spatial graph modeling and advanced molecular simulation, setting it apart from traditional drug discovery methods.
  • Their AI platform, GEMS, is capable of generating novel drug-like molecules and making rapid, accurate predictions for challenging targets, which is a significant competitive advantage.
  • Strategic partnerships with major pharmaceutical companies like Eli Lilly and significant funding rounds, including a $200M Series B, underscore their strong market position.

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

INACTIVE